Andrew Amiel

CARE FOR ALL. It’s not just a motto. It’s Antidote’s purpose, our business model – and our ethos. Why? In the U.S. alone, more than 82 million people don’t have adequate health insurance. That is an injustice. It is bad for the economy. And it is morally indefensible. We strive to attain a world in which every human being has access to affordable quality healthcare, no matter their race, location, or circumstance. Access to affordable healthcare means more than being able to see a doctor when you’re sick. It means being able to live your life fully, without unnecessary barriers and fear. In fact, we steadfastly believe that quality everyday healthcare is a basic human right. This world we’re trying to achieve is one in which we all look out for each other, and no one gets left behind. That is why we created Antidote Health. Our services are designed for everyone, regardless of their current health status or financial resources, and are based on a simple premise: the cost of healthcare can be reduced by making people healthier and keeping them that way. We are revolutionizing the way healthcare is paid for and delivered, putting most of the services patients need under one roof, making them affordable and simplifying the entire process. We take care of our patients’ health and quality of life, inspired by the most fundamental element of society: the community. No community is truly healthy if one of its members is sick. And whenever one of its members flourishes, the entire community does. We’re all in this together. And we all deserve good healthcare. All of us. Everyone. We’re working to create a better world, in which no one is left behind.

Carthera® is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices to treat a wide range of severe brain disorders. Carthera® has developed a proprietary device called SonoCloud®- a groundbreaking medical device that emits ultrasound to temporarily increase the permeability of the blood vessels in the brain. By using SonoCloud®, the therapeutic efficacy of new and existing therapies can be unlocked and harnessed to improve the treatment of a wide range of brain diseases: oncology indications (glioblastoma, brain metastasis) or neurodegenerative diseases (such as Alzheimer’s Disease, ALS). The products developed by Carthera® are in clinical or preclinical evaluation (not FDA or CE approved) and are not available for sale.

LumiThera, Inc. is an ophthalmic medical device company that is Harnessing the Power of Light™ to offer a comprehensive approach for detecting, treating, and monitoring retinal diseases, specifically dry age-related macular degeneration (AMD). LumiThera is the leader in ophthalmic photobiomodulation (PBM) innovation with its flagship product, the Valeda® Light Delivery System. Multiwavelength Valeda treatments are for patients suffering from dry AMD. Valeda is FDA Authorized in the US, CE Marked in the EU, and available in select countries in Latin America. AdaptDx Pro® is a portable dark adaptometer that utilizes AI to deliver a uniform patient experience. AdaptDx Pro is available in the U.S. and Canada. NOVA Vision Testing System is a comprehensive electrophysiology platform that provides objective assessment of the entire pathway for visual and neuro-visual disorders. VEP is available in the U.S. and select countries outside of the U.S. ERG is only available outside of the U.S. For more information on Valeda, visit www.lumithera.com. AdaptDx Pro and NOVA are available through LumiThera Diagnostics, Inc. and Diopsys, Inc., respectively.

CARE FOR ALL. It’s not just a motto. It’s Antidote’s purpose, our business model – and our ethos. Why? In the U.S. alone, more than 82 million people don’t have adequate health insurance. That is an injustice. It is bad for the economy. And it is morally indefensible. We strive to attain a world in which every human being has access to affordable quality healthcare, no matter their race, location, or circumstance. Access to affordable healthcare means more than being able to see a doctor when you’re sick. It means being able to live your life fully, without unnecessary barriers and fear. In fact, we steadfastly believe that quality everyday healthcare is a basic human right. This world we’re trying to achieve is one in which we all look out for each other, and no one gets left behind. That is why we created Antidote Health. Our services are designed for everyone, regardless of their current health status or financial resources, and are based on a simple premise: the cost of healthcare can be reduced by making people healthier and keeping them that way. We are revolutionizing the way healthcare is paid for and delivered, putting most of the services patients need under one roof, making them affordable and simplifying the entire process. We take care of our patients’ health and quality of life, inspired by the most fundamental element of society: the community. No community is truly healthy if one of its members is sick. And whenever one of its members flourishes, the entire community does. We’re all in this together. And we all deserve good healthcare. All of us. Everyone. We’re working to create a better world, in which no one is left behind.

Carthera® is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices to treat a wide range of severe brain disorders. Carthera® has developed a proprietary device called SonoCloud®- a groundbreaking medical device that emits ultrasound to temporarily increase the permeability of the blood vessels in the brain. By using SonoCloud®, the therapeutic efficacy of new and existing therapies can be unlocked and harnessed to improve the treatment of a wide range of brain diseases: oncology indications (glioblastoma, brain metastasis) or neurodegenerative diseases (such as Alzheimer’s Disease, ALS). The products developed by Carthera® are in clinical or preclinical evaluation (not FDA or CE approved) and are not available for sale.

LumiThera, Inc. is an ophthalmic medical device company that is Harnessing the Power of Light™ to offer a comprehensive approach for detecting, treating, and monitoring retinal diseases, specifically dry age-related macular degeneration (AMD). LumiThera is the leader in ophthalmic photobiomodulation (PBM) innovation with its flagship product, the Valeda® Light Delivery System. Multiwavelength Valeda treatments are for patients suffering from dry AMD. Valeda is FDA Authorized in the US, CE Marked in the EU, and available in select countries in Latin America. AdaptDx Pro® is a portable dark adaptometer that utilizes AI to deliver a uniform patient experience. AdaptDx Pro is available in the U.S. and Canada. NOVA Vision Testing System is a comprehensive electrophysiology platform that provides objective assessment of the entire pathway for visual and neuro-visual disorders. VEP is available in the U.S. and select countries outside of the U.S. ERG is only available outside of the U.S. For more information on Valeda, visit www.lumithera.com. AdaptDx Pro and NOVA are available through LumiThera Diagnostics, Inc. and Diopsys, Inc., respectively.

Providing technology entrepreneurs and their investors with independent corporate finance advice to help them evaluate, develop and execute growth strategies: Under secondment we provide a range of services including capital raising, M&A and strategic advisory. Services for our clients include: FOR GROWTH COMPANIES: - Equity Capital Markets - Strategic Advisory / Valuation Services - Mergers and Acquisitions (M&A, buyside and sellside) FOR INVESTORS: - Active Portfolio Development - Portfolio Company Services (financing, M&A and exits) FOR CORPORATES: - Minority Investments - M&A Buyside - M&A Divestments - Strategic Advisory / Valuation Services Our range of sector expertise covers the whole spectrum of the Technology industry, including: - IT software and services - Computer hardware and semiconductors - Telecom software and equipment - Internet-enabled services - Telecom services (new technology carriers) - New media and content (particularly for wireless applications) Our activities are pan-European in scope, with particular strength in the UK, France, Switzerland, Benelux and Scandinavia, and a growing interest in Germany.